Efficacy and safety of camrelizumab plus apatinib compared to apatinib monotherapy as third‐line or above therapy for metastatic colorectal cancer patients: A retrospective cohort study
Abstract:What Is Known and Objective
Programmed cell death protein‐1 (PD‐1) inhibitors synergize apatinib for anti‐tumour effect by regulating tumour microenvironment, vascular endothelial growth factor, hypoxia condition, immune response, etc. This study aimed to investigate the treatment efficacy and safety of camrelizumab (PD‐1 inhibitor) plus apatinib as third‐line or above therapy in metastatic colorectal cancer (mCRC) patients.
Methods
Totally, 64 unresectable mCRC patients receiving camrelizumab plus apatinib (N… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.